Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QK8 | ISIN: US05330T2050 | Ticker-Symbol:
NASDAQ
02.07.25 | 21:49
1,500 US-Dollar
+5,63 % +0,080
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
AUTONOMIX MEDICAL INC Chart 1 Jahr
5-Tage-Chart
AUTONOMIX MEDICAL INC 5-Tage-Chart

Aktuelle News zur AUTONOMIX MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAutonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase ("PoC 2") of Proof-of-Concept Human Clinical Study86Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1...
► Artikel lesen
FrAutonomix erhält US-Patent für nervensensitive Medizintechnologie5
FrAutonomix receives US patent for nerve-sensing medical technology1
FrAutonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology360Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity...
► Artikel lesen
05.06.Autonomix set to expand cancer pain treatment trial2
AUTONOMIX MEDICAL Aktie jetzt für 0€ handeln
05.06.Autonomix erweitert klinische Studie zur Behandlung von Krebsschmerzen-
05.06.Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain4
29.05.Autonomix Medical, Inc. - 10-K, Annual Report2
22.05.AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech2
16.05.Autonomix picks up key nerve ablation catheter patent1
14.05.Autonomix Medical, Inc.: Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event1
13.05.Autonomix plans expansion phase for cancer pain trial2
13.05.Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market236Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase ("PoC 2") of proof-of-concept trial; Access Here Additional indications potentially double...
► Artikel lesen
05.05.Autonomix reports significant pain relief in cancer trial2
05.05.Autonomix Medical, Inc.: Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain212Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here...
► Artikel lesen
01.05.Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain1
30.04.Autonomix Medical Reports Positive Results In First Human Trial For Cancer Pain, Stock Down1
30.04.Autonomix erzielt Fortschritte bei Schmerzbehandlung in Krebsstudien2
30.04.Autonomix advances pain treatment in cancer trials1
30.04.Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain112Initial trial phase ("PoC 1") achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and...
► Artikel lesen
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1